Advanced

Using albumin to improve the therapeutic properties of diabetes treatments.

Ahrén, Bo LU and Burke, B (2012) In Diabetes, Obesity and Metabolism 14. p.121-129
Abstract
Achieving tight glycaemic control remains an unmet need for many patients with type 2 diabetes, despite improved treatments. In order to meet glycaemic targets, attempts have been made to improve existing drugs and to develop new classes of drugs. Recent advances include insulin analogues that more closely mimic physiologic insulin levels, and incretin-based therapies, which capitalise on the glucoregulatory properties of native glucagon-like peptide-1 (GLP-1). Although promising, these agents are associated with limitations, including hypoglycaemia with insulin, gastrointestinal adverse events with GLP-1 receptor agonists and frequent dosing with both classes. Albumin is an abundant natural drug carrier that has been used to improve the... (More)
Achieving tight glycaemic control remains an unmet need for many patients with type 2 diabetes, despite improved treatments. In order to meet glycaemic targets, attempts have been made to improve existing drugs and to develop new classes of drugs. Recent advances include insulin analogues that more closely mimic physiologic insulin levels, and incretin-based therapies, which capitalise on the glucoregulatory properties of native glucagon-like peptide-1 (GLP-1). Although promising, these agents are associated with limitations, including hypoglycaemia with insulin, gastrointestinal adverse events with GLP-1 receptor agonists and frequent dosing with both classes. Albumin is an abundant natural drug carrier that has been used to improve the half-life, tolerability and efficacy of a number of bioactive agents. Here we review the physiologic roles of albumin and how albumin technologies are being used to prolong duration of action of therapies for diabetes, including insulin and incretin-based therapies. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Diabetes, Obesity and Metabolism
volume
14
pages
121 - 129
publisher
Wiley-Blackwell
external identifiers
  • wos:000298784900003
  • pmid:21812895
  • scopus:84855356092
ISSN
1462-8902
DOI
10.1111/j.1463-1326.2011.01482.x
language
English
LU publication?
yes
id
c388fb26-9438-4a87-afe8-898571b6ffc7 (old id 2151556)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/21812895?dopt=Abstract
date added to LUP
2011-09-04 16:34:38
date last changed
2017-01-01 07:38:37
@article{c388fb26-9438-4a87-afe8-898571b6ffc7,
  abstract     = {Achieving tight glycaemic control remains an unmet need for many patients with type 2 diabetes, despite improved treatments. In order to meet glycaemic targets, attempts have been made to improve existing drugs and to develop new classes of drugs. Recent advances include insulin analogues that more closely mimic physiologic insulin levels, and incretin-based therapies, which capitalise on the glucoregulatory properties of native glucagon-like peptide-1 (GLP-1). Although promising, these agents are associated with limitations, including hypoglycaemia with insulin, gastrointestinal adverse events with GLP-1 receptor agonists and frequent dosing with both classes. Albumin is an abundant natural drug carrier that has been used to improve the half-life, tolerability and efficacy of a number of bioactive agents. Here we review the physiologic roles of albumin and how albumin technologies are being used to prolong duration of action of therapies for diabetes, including insulin and incretin-based therapies.},
  author       = {Ahrén, Bo and Burke, B},
  issn         = {1462-8902},
  language     = {eng},
  pages        = {121--129},
  publisher    = {Wiley-Blackwell},
  series       = {Diabetes, Obesity and Metabolism},
  title        = {Using albumin to improve the therapeutic properties of diabetes treatments.},
  url          = {http://dx.doi.org/10.1111/j.1463-1326.2011.01482.x},
  volume       = {14},
  year         = {2012},
}